The phase I clinical trial, the first cord blood trial to be given the go-ahead by the US Food and Drug Administration (FDA), will determine the safety of the treatment. The team from the Children’s Memorial Hermann Hospital in Houston will recruit ten children, aged six weeks to 18 months, who developed hearing loss after birth.
Posted February 13, 2012.